With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

SHELTON, CT / ACCESS Newswire Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC) (the 'Company'), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.
Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA (https://www.today.com/health/coronavirus/new-covid-variant-nb181-nimbus-symptoms-rcna212304).
Nimbus has been rising globally since Spring according to WHO (https://cdn.who.int/media/docs/default-source/documents/epp/tracking-sars-cov-2/23052025_nb.1.8.1_ire.pdf).
Nimbus causes 'razor-sharp' sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.
Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.
Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.
Recently, the Influenza A H5N1 virus from a dairy worker in Michigan was found to be capable of airborne transmission in a ferret animal model [1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.
Additionally, a new genotype of H5N1 in Cambodia has caused four fatalities and fifth severe infection as of today (https://www.cidrap.umn.edu/avian-influenza-bird-flu/h5n1-avian-flu-infects-fifth-patient-cambodia).
NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.
NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.
Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.
NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.
COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.
NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.
NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.
NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.
'NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,' said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, 'We have US-based cGMP manufacturing capabilities already set up as well.'
Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.
Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).
Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.
The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.
About NanoViricides
NanoViricides, Inc. (the 'Company') (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development.
[1] Brock N, Pulit-Penaloza JA, Belser JA, et al. Avian Influenza A(H5N1) Isolated from Dairy Farm Worker, Michigan, USA. Emerging Infectious Diseases. 2025;31(6):1253-1256. doi:10.3201/eid3106.250386.
SOURCE: NanoViricides, Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Associated Press

3 hours ago

• Associated Press

Does Hospital Indemnity Insurance Help Cover Recurring Stays?

NEW YORK, NY / ACCESS Newswire / June 21, 2025 / A three-day stay in the hospital costs an average of $30,000 in the United States.1 While health insurance can help reduce your out-of-pocket costs if you have to be admitted to the hospital, there are contingent costs that may not be covered by your insurer. The cost of hospital stays, and other expenses like childcare could have a significant impact while you are unable to work. A hospital indemnity insurance policy can help with these costs. Here, we explore what health insurance helps cover and how the cash benefits of hospital indemnity insurance can help fill coverage gaps relating to recurring hospital stays. What does health insurance help cover? Many people receive health insurance through their employer, which can help with the cost of a hospital stay. Employer-sponsored health insurance plans cost an average of $111 per month, while Marketplace plans cost an average of $456 per month.2 So, if you're wondering, " How much is health insurance ?,' the answer depends on your specific circumstances and plan options. Marketplace health insurance plans typically cover a range of essential health benefits, including:3 Outpatient services Emergency services Hospitalization for surgery or overnight stays Pregnancy, maternity and newborn care Mental health and behavioral health treatment Prescription drugs Rehabilitative and habilitative services and devices Laboratory services Preventive and wellness services Chronic disease management Pediatric services Hospital costs are usually covered at least in part by primary health insurance plans, but you'll still have to pay copays and deductibles, and your health insurance plan may be subject to coverage limits. What is hospital indemnity insurance? Hospital indemnity insurance is a supplemental plan that can help fill gaps in your primary health insurance. It's not a replacement for health insurance but can help you with unexpected expenses and provide additional support if you've had multiple hospital stays that forced you to reach a coverage limit. Hospital indemnity insurance works similarly to health insurance in that you pay premiums to an insurance provider in exchange for coverage. You may have access to a plan through your employer, or you can purchase an individual plan directly from an insurance company. Unlike health insurance, however, hospital indemnity insurance plans typically pay eligible cash benefits based on the policy option you choose. You can use the benefits in any way you see fit, such as: Out-of-pocket medical expenses Childcare Living expenses like groceries, rent and utilities Plans may function differently between providers, but typically, you can file a claim for care provided while in the hospital, and your insurance provider pays eligible claims to help you with the costs of your hospital stay. Why is hospital indemnity insurance worth it? There are a number of reasons why you might consider a hospital indemnity insurance plan. These may include: Added financial assistance: Hospital stays can be expensive, especially if you have to go multiple times in the same year. Hospital indemnity insurance helps provide added financial support for recurring visits. Flexibility: Health insurance plans typically pay the hospital directly for treatment. But hospital indemnity insurance pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use it for both medical and non-medical costs. Surpassing coverage limits: If you've reached a health insurance coverage limit after being admitted to the hospital several times, you could still use the hospital indemnity insurance. Ultimately, if you think you or a family member will have multiple stays at the hospital in a given year, hospital indemnity insurance could help provide some added peace of mind. The bottom line Hospital indemnity insurance provides coverage options that can help with recurring hospital stays. This supplemental policy pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use your benefits to help fill gaps in your health insurance coverage or help pay living expenses. Consider applying for a hospital indemnity insurance policy for added peace of mind. Sources: 1 - Why health insurance is important. Accessed May 12, 2025. 2 Ramsey Solutions - How Much Does Health Insurance Cost? Updated May 12, 2025. Accessed May 12, 2025. 3 - Health benefits & coverage. Accessed May 12, 2025. Content within this article is provided for general informational purposes and is not provided as tax, legal, health, or financial advice for any person or for any specific situation. Employers, employees, and other individuals should contact their own advisers about their situations. For complete details, including availability and costs of Aflac insurance, please contact your local Aflac agent. Aflac coverage is underwritten by American Family Life Assurance Company of Columbus. In New York, Aflac coverage is underwritten by American Family Life Assurance Company of New York. Hospital, B40000 series: In Delaware, Policies B40100DE & B4010HDE. In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. In Pennsylvania, Policies B40100PA & B4010HPA. In Virginia, Policies B40100VA & B4010HVA. Coverage may not be available in all states, including but not limited to DE, ID, NJ, NM, NY, VA or VT. Benefits/premium rates may vary based on state and plan levels. Optional riders may be available at an additional cost. Policies and riders may also contain a waiting period. Refer to the exact policy and rider forms for benefit details, definitions, limitations, and exclusions. Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999 CONTACT: Senior PR & Corporate Communications Contact: Angie Blackmar, 706-392-2097 or [email protected] SOURCE: Aflac press release

Chicago Tribune

5 hours ago

• Chicago Tribune

US measles count now tops 1,200 cases, and Iowa announces an outbreak

The U.S. logged fewer than 20 measles cases this week, though Iowa announced the state's first outbreak Thursday and Georgia confirmed its second Wednesday. There have been 1,214 confirmed measles cases this year, the Centers for Disease Control and Prevention said Friday. Health officials in Texas, where the nation's biggest outbreak raged during the late winter and spring, confirmed six cases in the last week. There are three other major outbreaks in North America. The longest, in Ontario, Canada, has resulted in 2,179 cases from mid-October through June 17. The province logged its first death June 5 in a baby who got congenital measles but also had other preexisting conditions. Another outbreak in Alberta, Canada, has sickened 996 as of Thursday. And the Mexican state of Chihuahua had 2,335 measles cases and four deaths as of Friday, according to data from the state health ministry. Other U.S. states with active outbreaks — which the CDC defines as three or more related cases — include Arizona, Colorado, Illinois, Kansas, Montana, New Mexico, North Dakota and Oklahoma. In the U.S., two elementary school-aged children in the epicenter in West Texas and an adult in New Mexico have died of measles this year. All were unvaccinated. Measles vaccination rates drop after COVID-19 pandemic in counties across the USMeasles is caused by a highly contagious virus that's airborne and spreads easily when an infected person breathes, sneezes or coughs. It is preventable through vaccines and has been considered eliminated from the U.S. since 2000. There are a total of 750 cases across 35 counties, most of them in West Texas, state health officials said Tuesday. Throughout the outbreak, 97 people have been hospitalized. State health officials estimated less than 1% of cases — fewer than 10 — are actively infectious. Fifty-five percent of Texas' cases are in Gaines County, where the virus started spreading in a close-knit, undervaccinated Mennonite community. The county has had 413 cases since late January — just under 2% of its residents. The April 3 death in Texas was an 8-year-old child, according to Health Secretary Robert F. Kennedy Jr. Local health officials said the child did not have underlying health conditions and died of 'what the child's doctor described as measles pulmonary failure.' A unvaccinated child with no underlying conditions died of measles in Texas in late February; Kennedy said the child was 6. New Mexico held steady Friday with a total of 81 cases. Seven people have been hospitalized since the outbreak started. Most of the state's cases are in Lea County. Sandoval County near Albuquerque has six cases, Eddy County has three, Doña Ana County has two. Chaves, Curry and San Juan counties have one each. An unvaccinated adult died of measles-related illness March 6. The person did not seek medical care. Oklahoma added one case Friday for a total of 17 confirmed and three probable cases. The state health department is not releasing which counties have cases. Arizona has four cases in Navajo County. They are linked to a single source, the county health department said June 9. All four were unvaccinated and had a history of recent international travel. Colorado has seen a total of 16 measles cases in 2025, which includes one outbreak of 10 related cases. The outbreak is linked to a Turkish Airlines flight that landed at Denver International Airport in mid-May. Four of the people were on the flight with the first case — an out-of-state traveler not included in the state count — while five got measles from exposure in the airport and one elsewhere. Health officials are also tracking an unrelated case in a Boulder County resident. The person was fully vaccinated but had 'recently traveled to Europe, where there are a large number of measles cases,' the state health department said. Other counties that have seen measles this year include Archuleta and Pueblo. Georgia has an outbreak of three cases in metro Atlanta, with the most recent infection confirmed Wednesday. The state has confirmed six total cases in 2025. The remaining three are part of an unrelated outbreak from January. Illinois health officials confirmed a four-case outbreak on May 5 in the far southern part of the state. It grew to eight cases as of June 6, but no new cases were reported in the following weeks, according to the Illinois Department of Public Health. The state's other two cases so far this year were in Cook County, and are unrelated to the southern Illinois outbreak. Illinois unveils online tool showing measles vaccination rates by schoolIowa has had six total measles cases in 2025. Four are part of an outbreak in eastern Johnson County, among members of the same household. County health officials said the people are isolating at home, so they don't expect additional spread. Kansas has a total of 79 cases across 11 counties in the southwestern part of the state, with three hospitalizations. All but three of the cases are connected, and most are in Gray County. Montana had 22 measles cases as of Friday. Fourteen were in Gallatin County, which is where the first cases showed up — Montana's first in 35 years. Flathead and Yellowstone counties had two cases each, and Hill County had four cases. There are outbreaks in neighboring North Dakota and the Canadian provinces of Alberta, British Columbia and Saskatchewan. North Dakota, which hadn't seen measles since 2011, was up to 34 cases as of June 6, but has held steady since. Two of the people have been hospitalized. All of the people with confirmed cases were not vaccinated. There were 16 cases in Williams County in western North Dakota on the Montana border. On the eastern side of the state, there were 10 cases in Grand Forks County and seven cases in Cass County. Burke County, in northwest North Dakota on the border of Saskatchewan, Canada, had one case. Measles cases also have been reported this year in Alaska, Arkansas, California, District of Columbia, Florida, Hawaii, Indiana, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New York, Rhode Island, South Dakota, Vermont, Virginia and Washington. Health officials declared earlier outbreaks in Indiana, Michigan, Ohio and Pennsylvania over after six weeks of no new cases. Tennessee's outbreak also appears to be over. Cases and outbreaks in the U.S. are frequently traced to someone who caught the disease abroad. The CDC said in May that more than twice as many measles have come from outside of the U.S. compared to May of last year. Most of those are in unvaccinated Americans returning home. In 2019, the U.S. saw 1,274 cases and almost lost its status of having eliminated measles. The best way to avoid measles is to get the measles, mumps and rubella vaccine. The first shot is recommended for children between 12 and 15 months old and the second between 4 and 6 years old. Getting another MMR shot as an adult is harmless if there are concerns about waning immunity, the CDC says. People who have documentation of receiving a live measles vaccine in the 1960s don't need to be revaccinated, but people who were immunized before 1968 with an ineffective vaccine made from 'killed' virus should be revaccinated with at least one dose, the agency said. People who have documentation that they had measles are immune and those born before 1957 generally don't need the shots because so many children got measles back then that they have 'presumptive immunity.' Measles has a harder time spreading through communities with high vaccination rates — above 95% — due to 'herd immunity.' But childhood vaccination rates have declined nationwide since the pandemic and more parents are claiming religious or personal conscience waivers to exempt their kids from required shots. Measles first infects the respiratory tract, then spreads throughout the body, causing a high fever, runny nose, cough, red, watery eyes and a rash. The rash generally appears three to five days after the first symptoms, beginning as flat red spots on the face and then spreading downward to the neck, trunk, arms, legs and feet. When the rash appears, the fever may spike over 104 degrees Fahrenheit, according to the CDC. Most kids will recover from measles, but infection can lead to dangerous complications such as pneumonia, blindness, brain swelling and death. There's no specific treatment for measles, so doctors generally try to alleviate symptoms, prevent complications and keep patients comfortable.

Epoch Times

7 hours ago

• Epoch Times

How Women Can Prevent Hair Loss by Nourishing the Liver and Kidneys

Hair health reflects overall physical well-being. Women often experience hair loss due to various causes, including postpartum recovery, menopause, alopecia areata, or scalp issues such as itchiness and dandruff, exacerbated by summer heat. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing a blend of targeted dietary supplements, meticulous scalp care, and proper hair-washing techniques to reduce hair loss effectively. Dr. Chen Hsin-hung, a TCM practitioner at Hanyitang Chinese Medicine clinics in Taiwan, shared a case of hair loss. A woman in her 20s developed alopecia areata (patchy baldness) after receiving the COVID-19 vaccine, which left her deeply distressed when her hair almost entirely fell out. Through 6 to 8 months of TCM treatment, she regrew dark, vibrant hair. Exploring Hair Loss Causes With TCM From the perspective of TCM, the liver and kidneys are closely related to hair health as they play a vital role in the internal organ-centered energy system.